Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 25, 2025 • 10:31 PM ET

Date/Time Source News Release
04/23/2025 08:30 AM EDT Business Wire CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia-Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
04/08/2025 09:51 AM EDT Business Wire New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
03/24/2025 09:00 AM EDT Business Wire CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
03/18/2025 04:05 PM EDT Business Wire CEL-SCI Announces Closing of $2.5 Million Offering
03/17/2025 03:24 PM EDT Business Wire CEL-SCI Announces Pricing of $2.5 Million Offering
03/17/2025 08:00 AM EDT Business Wire CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review-in Talks with Potential Partners Interested in Commercialization of Multikine
03/14/2025 08:30 AM EDT Business Wire Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
02/20/2025 08:00 AM EST Business Wire CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
02/18/2025 08:30 AM EST Business Wire CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
01/14/2025 09:00 AM EST Business Wire CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
Page

Additional News

As of April 25, 2025 • 10:31 PM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.